Once you see…
…the importance of targeting METex14 skipping, you can’t ignore it
…the importance of targeting METex14 skipping, you can’t ignore it
months is the median OS of METex14 skipping NSCLC patients without treatment with MET inhibitor therapy
months is the median OS of METex14 skipping NSCLC patients following treatment with MET inhibitor therapy
MET inhibitors are highly specific and offer fewer off-target effects compared to other MET inhibitors
The success of small molecules in the treatment of cancer have proven that identification of a correct target in cancer patients is crucial for the success of therapy. [Hoelder 2012] Until recently, clinical trials have demonstrated little progress in MET inhibition for NSCLC patients due to lack of appropriately identified patients. [Seimann 2018] The identification of patients harboring primary oncogenic drivers like MET could facilitate personalized medicine, allowing for optimal management of your patients’ health. [NHS 2019]
There are two subtypes of type I inhibitors; type Ia and type Ib:
Although there have been many treatment advancements in NSCLC, there remains a significant urgent unmet need for patients with METex14 skipping NSCLC. [Awad 2019][Wolf 2018][Sabari 2018]
NSCLC patients harboring METex14 skipping demonstrate a poor response to standard of care, such as chemotherapy and immune checkpoint inhibitors. [Awad 2019]
In an analysis of patients with MET-altered NSCLC treated with MET inhibitor therapy vs. those treated with chemotherapy, patients receiving MET inhibitor therapy demonstrated a median OS of greater than 2 years compared to just 8 months with chemotherapy. [
months is the median OS of METex14 skipping NSCLC patients treated with chemotherapy
months is the median OS of METex14 skipping NSCLC patients following treatment with MET inhibitor therapy
Additionally, data demonstrates that even in NSCLC patients with concomitant METex14 skipping and high PD-L1 expression, the efficacy of immunotherapy remains poor.
In a retrospective analysis of NSCLC patients with METex14 skipping (n=11/24 with PD-L1 ≥50%), ORR was just 17% and median PFS just 1.9 months following treatment with single or combination immunotherapy. [Sabari 2018]
REFERENCES AND ABBREVIATIONS
Este website tem como objetivo educar e informar os profissionais de saúde sobre CPNPC.